Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1

Interventions

pembrolizumab 3lenvatinib 2Specimen Handling 2Nivolumab 2Cisplatin 2trastuzumab deruxtecan 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1entinostat 1dostarlimab 1bintrafusp alfa protein, human 1aldesleukin 1Therapeutic Touch 1Surveys and Questionnaires 1Respiratory Function Tests 1Radiotherapy 1Radiation 1Prochlorperazine 1Positron-Emission Tomography 1Platinum 1Paclitaxel 1Ondansetron 1O(6)-codeine methyl ether 1Nelfinavir 1Meperidine 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Loperamide 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Bupropion × 90 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡